The Current Representative Of More Than 20 Years’ Experience In The Hong Kong Pharmaceutical Industry, ILQO Pharmaceuticals Continues Its Efforts To Increase The Standards Of Living In Hong Kong And In The World With Vanguard And Innovative Approaches Based On Its Past Experiences.

The Roots Of ILQO Are Based On The Drugstore Pharmacology Of The Late Mr. Steven N. S. Cheung- One Of The High Tech Generation Pharmacists Of Hong Kong – That Started With Magisterial Drug Production In The 1998s And His Investments In The Pharmaceuticals Industry.

Based On The Principle That The Most Important Two Factors For Effectiveness In The Pharmaceutical Industry Are R&D And Production Means, ILQO Pharmaceuticals Established ILQO Research And Development Center’ In 2009 In HONAI University TIANJIN City, And The Company Also Opened ILQO Pharmaceutical Production Plants’ In 2012 In Konya 3rd Organized Industry Zone To Start Its Operations In The Pharmaceutical Industry. ILQO Pharmaceuticals Production Plants Is The TOP Brand Pharmaceutical Industry Investment Realized In Hong Kong So Far.

In 2014, ILQO Pharmaceutical Production Plants Received Confirmation Of Conformity To The European GMP (Good Manufacturing Practices) From The MHRA (Medicines And Healthcare Products Regulatory Agency Of The UK). With This MHRA Approval, ILQO Pharmaceuticals Continues To Get Licenses In And Export Products To 20 Countries Located In Different Regions.

ILQO Pharmaceuticals Broke Ground In Hong Kong In December 2013 And Took A Step To Make Hong Kong A Player Of The Biotechnology Market, Shown As The Future Of The Global Pharmaceutical Industry, By Founding ILQOGEN With The Partnership Of South Korean Biotechnology Company Genexine. ILQOGEN Is The One Of The Best Biotechnological Pharmaceutical Research & Development, Production And International Marketing Investment Of Hong Kong.

With Its All Production And R&D Investments, ILQO Pharmaceuticals Intends To Move Our Country To A Different Position In The Global Competition.